Welcome to our dedicated page for BECTON DICKINSON & CO SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BECTON DICKINSON & CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BECTON DICKINSON & CO's regulatory disclosures and financial reporting.
Becton Dickinson & Co executive Peter Menziuso, EVP and President of BDI, filed an initial Form 3 reporting his beneficial ownership status in the company’s common stock. The filing shows he held no shares of common stock directly as of the reported date.
Becton, Dickinson and Company resumed U.S. shipments of its ChloraPrep™ product after a voluntary ship hold while it conducted additional final release testing. The company had previously placed both ChloraPrep™ and PurPrep™ on ship hold in the U.S. on May 6, 2026.
The ship hold was implemented in response to an FDA Warning Letter for BD’s El Paso manufacturing facility and to allow additional release testing. BD states that all additional final release testing to date has been acceptable and that there have been no patient safety signals.
The company refers investors to its latest Annual Report on Form 10-K, its Form 10-Q for the period ended March 31, 2026, and other SEC filings for a detailed discussion of the El Paso Warning Letter, related risks, and broader forward-looking risk factors.
Becton Dickinson & Co Executive Vice President and Chief Revenue Officer Michael Feld sold 75 shares of Common Stock in an open-market transaction at $147.35 per share. After this sale, he directly holds 21,084 shares of the company.
Form 144 notice of proposed sale and recent Rule 10b5-1 sales. The filing lists 75 Restricted Stock Units of Common Stock stated as securities to be sold, with an associated date of 08/20/2025. The excerpt also records two recent 10b5-1 sales by Michael Feld: 74 shares on 04/27/2026 for $11,243.56 and 75 shares on 03/26/2026 for $11,762.25. The broker/filer shown is Morgan Stanley Smith Barney LLC and the security is listed on the NYSE.
Becton, Dickinson and Company, through its Luxembourg finance subsidiary Becton Dickinson Euro Finance S.à r.l., issued €600,000,000 of 3.855% senior unsecured notes due 2033. The notes are fully and unconditionally guaranteed by BD and carry standard covenants and events of default.
BD and Becton Finance expect to use the net proceeds, together with cash on hand, to repay the entire principal outstanding on Becton Finance’s 1.208% notes due June 4, 2026, plus accrued interest, fees and expenses, with any remaining proceeds available for general corporate purposes.
BECTON DICKINSON AND CO ownership update: T. Rowe Price Investment Management, Inc. reports beneficial ownership of 9,673,586 shares of Common Stock, representing 3.4% of the class. The filing lists sole voting power for 9,066,401 shares and sole dispositive power for 9,673,586 shares. The amendment is signed by Ellen York, Vice President, on 05/15/2026.
Becton, Dickinson and Company, through its Luxembourg subsidiary Becton Dickinson Euro Finance S.à r.l., entered into an underwriting agreement to issue €600,000,000 aggregate principal amount of 3.855% Notes due 2033. The new Euro Notes will be fully and unconditionally guaranteed on a senior unsecured basis by BD.
BD and Becton Finance expect to use the net proceeds from this offering, together with cash on hand, to repay the outstanding 1.208% Euro Notes due June 4, 2026, including accrued interest, fees and expenses. Completion of the offering is expected on or about May 20, 2026, subject to customary closing conditions.
Becton Dickinson Euro Finance S.à r.l. proposes a euro-denominated notes offering fully and unconditionally guaranteed by Becton, Dickinson and Company. The prospectus supplement describes annual euro interest, optional redemption mechanics (including a Par Call Date), a change-of-control repurchase at 101% and a tax‑related whole‑notice redemption right. Net proceeds are to be used, together with cash on hand, to repay the Issuer’s 1.208% Euro Notes due June 4, 2026. The notes will be issued in minimum denominations of €100,000, represented by global registered notes held under a common safekeeper for Euroclear and Clearstream, and listing on the NYSE has been requested.
Becton Dickinson & Co director Robert Luther Huffines received 210 derivative rights to common stock under the BD Deferred Compensation Plan. The rights were granted at a reference price of $149.04 per right and increase his total deferred rights to 404.
Each right converts into one share of common stock, and the securities are distributed after his service as a director ends or on dates he previously specified. The total also reflects rights acquired through dividend reinvestment and adjustments related to combining the Biosciences and Diagnostic Solutions businesses with Waters Corp.